Tavotek Biotherapeutics
- 18/11/2021
- Series B
- $35,000,000
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
- Industry Pharmaceutical Manufacturing
- Website https://www.tavotek.com/
- LinkedIn https://www.linkedin.com/company/tavotek/
Related People
Di ZhangFounder
Executive scientific leader with over 20 years drug discovery research experience in the biotechnology and pharmaceutical industries. Dynamic entrepreneur with experiences of building R&D capabilities from scratch for start-up biotech companies. Seasoned drug developer in the fields of antibody based biotherapeutics, gene editing and cell therapy, and small molecule drugs. Proud achiever with the development of two antibody drugs in clinical trial and multiple oncology drugs in preclinical development. Lead authors and inventors for dozens of research publications and patent applications.